APA (7th ed.) Citation

Li, Y., Xiao, Y., Chen, F., Xiao, S., Lin, J., Cai, S., . . . Li, S. (2024). PXDN as a pan-cancer biomarker and promotes tumor progress via immune inhibition in nasopharyngeal carcinoma. Frontiers in Oncology, 14, . https://doi.org/10.3389/fonc.2024.1463011

Chicago Style (17th ed.) Citation

Li, Yu-Chun, et al. "PXDN as a Pan-cancer Biomarker and Promotes Tumor Progress via Immune Inhibition in Nasopharyngeal Carcinoma." Frontiers in Oncology 14 (2024). https://doi.org/10.3389/fonc.2024.1463011.

MLA (9th ed.) Citation

Li, Yu-Chun, et al. "PXDN as a Pan-cancer Biomarker and Promotes Tumor Progress via Immune Inhibition in Nasopharyngeal Carcinoma." Frontiers in Oncology, vol. 14, 2024, https://doi.org/10.3389/fonc.2024.1463011.